Visual Universitätsmedizin Mainz

GMP-VTE

A prospective cohort study to identify and evaluate novel and established biochemical and genetic markers in venous thromboembolism and its secondary diseases.

  • Study directors:

    • Univ.-Prof. Dr. med. Philipp Wild, M.Sc. (Coordination)
    • Univ.-Prof. Dr. med. Stavros Konstantinides

Subject

Venous thromboembolism (VTE); pulmonary embolism; deep vein thrombosis (DVT)

Study design

Epidemiologic prospective cohort study

Study participants

A total of 664 individuals with acute pulmonary embolism and/or acute deep vein thrombosis (DVT)

Inclusion criteria

  • Age ≥ 18 Jahre and informed written consent
  • VTE diagnosis by standard imaging procedure

Status

664 study participants (evaluation)

Objectives

  • Identification of proteins that may influence disease development and prognosis of venous thromboembolism
  • Improvement of the biological understanding of venous thromboembolism
  • Potential identification of new VTE subtypes
  • Evaluation of new therapeutic targets

Study procedure

  • Baseline visit (clinical data, biomaterial, protein data and genotype data, platelet function subgroup)
  • Follow-up 3/6 months (clinical data, biomaterial, platelet function subgroup)
  • Follow-up 12 months (clinical data, biomaterial, protein data, platelet function subgroup)
  • Follow-up 24 months (clinical data, biomaterial, platelet function subgroup)

Summary

Previous scientific research has identified several clinical, genetic and acquired risk factors for venous thromboembolism (VTE). However, the molecular pathophysiology and mechanisms of disease progression are still largely unknown. This is reflected, among other things, in uncertainties regarding the primary and secondary prevention of VTE and the optimal duration of antithrombotic therapy. A growing body of literature points to clinically relevant differences between VTE phenotypes (e.g. deep vein thrombosis (DVT) vs. pulmonary embolism, unprovoked vs. provoked venous thromboembolic events). Extensive links to cardiovascular, inflammatory and immune-related diseases demonstrate the complexity of the disease. The GMP-VTE project is a prospective, multicenter cohort study of individuals with objectively confirmed VTE. Sequential data collection was performed at the time of the acute event and during serial follow-up. Different data layers (e.g. clinical, genetic, proteomic and platelet data) are available for multidimensional data analyses using advanced statistical, bioinformatics and machine learning methods.

The systems approach to the comprehensive dataset of the GMP-VTE project may provide new biological insights into the pathophysiology of VTE and improve our current understanding and management of VTE.

Back to studies/bio data banks